BI 409306, a potent and selective PDE9A inhibitor that may improve NMDA signalling, is currently under clinical development as a potential treatment for APS [8] and for prevention of relapse in schizophrenia [9]. The gene discussed is PDE9A; the disease is schizophrenia.